The transient receptor potential vanilloid 1 (TRPV1) channel, known as the heat and capsaicin (CAP) receptor, plays a crucial role in pain sensation. Although CAP and its analogs can induce topical analgesia, their use is limited by severe thermoregulatory side effects. Here, we provide robust evidence that the bone antiresorptive agent zoledronic acid (ZOL) exerts analgesic effects by inhibiting TRPV1. In vitro, ZOL suppresses CAP-evoked responses in dorsal root ganglion (DRG) neurons and reduces TRPV1 channel conductance in Xenopus laevis oocytes, inhibiting its activity over a broad concentration range by occluding the permeation pathway from both the extracellular and intracellular sides. In vivo, ZOL administration attenuates thermal nociceptive behaviors in mice and flies exposed to noxious heat. Moreover, ZOL prevents CAP- and TRPV1-mediated synaptic effects, mimicking the actions of the TRPV1 antagonist capsazepine. Collectively, these findings identify ZOL as a potent TRPV1 blocker and provide compelling mechanistic insight into its analgesic effects in vivo, positioning it as a promising scaffold for the development of novel pain-relief compounds.